2025 Disease Radiopharmaceuticals 
AuntMinnie
SEPTEMBER 25, 2024
Nuclear cardiologists could see significant reductions in Medicare reimbursements in 2025, according to a leading expert. million coronary artery disease procedures per year. Despite a proposal by the U.S. We would see a drop of approximately 3% in the reimbursement per SPECT study performed,” he said.
Imaging Technology
NOVEMBER 7, 2024
Under the new policy, CMS will unpackage and pay separately for diagnostic radiopharmaceuticals with per-day costs exceeding $630, removing financial barriers that have long hindered patient access to essential nuclear medicine diagnostic procedures. tim.hodson Thu, 11/07/2024 - 11:25 Nov.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Imaging Technology
JANUARY 5, 2024
milla1cf Fri, 01/05/2024 - 11:32 January 5, 2024 — NorthStar Medical Radioisotopes, LLC , a global innovator in development, production and commercialization of radiopharmaceuticals used to detect and treat cancer and other serious diseases, and Curadh MTR Inc. Chief Executive Officer of NorthStar Medical Radioisotopes.
AuntMinnie
JULY 10, 2024
Centers for Medicare and Medicaid Services (CMS) proposed a new reimbursement plan July 10 for diagnostic PET scans that would provide separate payments for radiopharmaceuticals, as well as an extra payment for hospitals when they use domestically produced technetium-99m (Tc-99m).
Imaging Technology
JULY 5, 2024
Lantheus intends to begin a Phase 1/2a study with 177Lu-DOTA-RM2 in prostate cancer patients in 2025. mtaschetta-millane Fri, 07/05/2024 - 06:00 July 5, 2024 — Lantheus Holdings, Inc. , 68Ga-DOTA-RM2 will be used as a companion diagnostic.
Imaging Technology
NOVEMBER 1, 2024
We also expect to see the full Phase 1 results presented at a scientific meeting in 2025." "The Front loading radioactivity and extending the time on therapy may lengthen time to disease progression. The available science increasingly highlights that fixed dosing at fixed intervals is unlikely to be optimal. 1 Ells, Zachary, et al.
Expert insights. Personalized for you.
64 
Let's personalize your content